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Abstract
Cardiac fibrosis is one of the most common pathological conditions caused by different heart diseases, including myocardial
infarction and diabetic cardiomyopathy. Cardiovascular disease is one of the major causes of mortality worldwide. Cardiac
fibrosis is caused by different processes, including inflammatory reactions and oxidative stress. The process of fibrosis begins by
changing the balance between production and destruction of extracellular matrix components and stimulating the proliferation
and differentiation of cardiac fibroblasts. Many studies have focused on finding drugs with less adverse effects for the treatment
of cardiovascular disease. Some studies show that nutraceuticals are effective in preventing and treating diseases, including
cardiovascular disease, and that they can reduce the risk. However, big clinical studies to prove the therapeutic properties of all
these substances and their adverse effects are lacking so far. Therefore, in this review, we tried to summarize the knowledge on
pathways and mechanisms of several nutraceuticals which have shown their usefulness in the prevention of cardiac fibrosis.
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Introduction
Cardiac fibrosis is one of the most well-known cardiac tissue
changes caused by different heart diseases. Cardiac fibrosis
begins with the proliferation of fibroblasts and the abnormal
replacement of a network of collagen fibers in the extracellular
matrix [1–3]. Several factors, including inflammatory factors
and cytokines, oxidative stress, cardiac hypertrophy, inducible
proliferation and differentiation of cardiac fibroblasts, and al-
tered signaling pathways, are involved in the development of
cardiac fibrosis. The progression of heart fibrosis causes ar-
rhythmia and eventually heart failure [4–6]. Many studies
have focused on finding drugs with less adverse effects for
the treatment of cardiovascular disease. A number of studies
show that nutraceuticals are effective in preventing and
treating diseases, including cardiovascular disease. However,
there are not many critical reviews and position papers giving
a simple definition of what nutraceuticals are and how useful
can they be in cardiovascular diseases [7–11]. Stephen L.
DeFelice first used the term “nutraceutical” in 1989 [7]. In
2011, DeFelice claimed that nutraceuticals were in fact a type
of food or dietary supplements that played a role in preventing
and treating diseases. In the year 2000, the US Nutraceutical
Research and Education on Nutraceuticals or functional foods
has defined it as a safe food supplement that can be useful in
prevention and disease management [7].
Thus, based on the studies and research performed until
today, it seems that nutraceuticals can be an effective
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therapeutic tool in improving cardiac fibrosis caused by dif-
ferent heart diseases. Nutraceuticals can, in addition to their
protective role for the cardiovascular system, improve cardiac
function. Since clinical trials on humans concerning cardiac
fibrosis are scarce, further studies should be designed to eval-
uate the possible benefits and disadvantages of nutraceuticals.
In this critical review, we try to summarize various nutraceu-
tical functional mechanisms on cardiac fibrosis based upon the
existing data. A summary of these mechanisms is provided in
Table 1.
Data sources
The included data were provided from Web of Science,
Cochrane, PubMed, and Scopus which were extracted from
the published studies in English until 20 March 2020 that
contained data on the effect of nutraceuticals on multiple sig-
naling pathways in cardiac fibrosis injury and repair with the
following medical case heading terms and/or text words:
nutraceuticals, berberine, curcumin,Hibiscus sabdariffa, flax-
seed, olive oil and garlic, and cardiac fibrosis injury and
repair.
Berberine
Berberine is a quaternary ammonium salt belonging to the
family of isoquinoline alkaloids. This alkaloid substance can
be found in plants from the Berberis family, including barber-
ry, blueberry, and turmeric. It has long been used in traditional
Chinese medicine and Ayurveda as an effective herbal remedy
in the treatment of various diseases [12–14]. The high anti-
inflammatory and antioxidant potential of berberine has been
shown in laboratory studies. The neuroprotective and cardio-
vascular protective effects of this substance have been con-
firmed in animal studies [13]. Numerous studies have also
shown that berberine can lower blood lipids in humans and
improve insulin resistance [13, 15–17]. Zhao and colleagues
[18] administered berberine to two groups of mice with high
blood pressure at doses of 5 and 10 mg/kg for 4 weeks, re-
spectively. At the end of this period, cardiac function and
nitric oxide levels, cyclic adenosine monophosphate levels,
myocardial fibrosis index factors such as left ventricular wall
thickness, intervertebral septal thickness, intercellular colla-
gen volume, and collagen areas around the vessels were eval-
uated. Decreased left ventricular wall thickness, decreased
intercellular collagen volume, decreased collagen areas
around the vessels, increased nitric oxide levels, and increased
cyclic adenosine monophosphate in these mice showed that
both doses of 5 and 10-mg berberine had beneficial effect.
Nitric oxide and cyclic adenosine monophosphate improve
cardiac contractility and prevent left ventricular fibrosis
remodeling [18]. Therefore, in this section, we will analyze
the mechanisms of action of berberine in the improvement of
cardiac fibrosis.
Berberine and Wnt/β-catenin signaling pathway
Recent studies have shown the protective role of the Wnt
signaling pathway in vascular cells involved in atherosclerosis
and heart damage [19–21]. β-catenin is one of the Wnt path-
way proteins. Laboratory studies showed that the levels of this
protein in damaged myocardial tissue increase after myocar-
dial infarction [22, 23]. Overexpression of Wnt pathway an-
tagonists, including sFRP1, reduces the size of the damaged
tissue and improves cardiac function. Thus, by inactivating
the Wnt signaling pathway, protective processes can be seen
in the rat heart [20]. However, some studies have suggested
the protective role of Wnt-activated pathway in the cardiovas-
cular system. The explanation of this contradiction might be
the differences in the models studied and the use of multiple
factors in investigating the activity of the Wnt pathway [20].
GSK3β is a serine/threonine kinase that plays an important
role in regulating the Wnt pathway in cardiac cells. This ki-
nase is involved in several signaling pathways [20]. A study
by Badimon et al. [20] shows that myocardial injury is re-
duced in mice in the presence of GSK3β inhibitors [20].
Another study also indicated that diabetic rats and cultured
rat hypertrophic cardiac cells show that berberine can improve
cardiac dysfunction and cardiac fibrosis by activating the
AMP-activated protein kinase (AMPK) [24, 25] and Akt path-
ways and inhibiting GSK3β [25]. Therefore, it might be rea-
sonable to conclude that berberine can block the Wnt pathway
by inhibiting GSK3β and activating the AMPK and Akt path-
way, and then improve cardiac fibrosis.
Berberine and fibroblast growth factor signaling
It was reported that IGF-1R expression in cardiac fibro-
blasts decreases in the presence of berberine [26].
Subsequently, matrix metalloproteinase (MMP-2/9) levels
are reduced in these cells and the process of fibroblast
differentiation and collagen accumulation does not occur
[26–28]. Berberine also prevents over-synthesis of type I
collagen fibers and α-smooth muscle actin filaments.
Berberine, with its anti-fibrotic properties, helps to main-
tain the heart function, especially in diabetes [26]. On the
other hand, berberine can prevent cardiac fibrosis by de-
creasing the expression of transforming growth factor-β1
(TGF-β1) and connective tissue growth factor (CTGF) as
well as reducing the synthesis of types I and III collagen
fibers. Berberine also reduces deposition of these collagen
fibers which is favorable. A study by Lu et al. [29] on
diabetic mice supports this mechanism of berberine [29].
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Table 1 Experimental studies of nutraceuticals in cardiac fibrosis
Nutraceuticals Doses Problem Model Findings Ref
Berberine 5 and 10 mg/kg
(orally)
High blood pressure and left
ventricular fibrosis
In vivo Improvement of cardiac contractility and left ventricular
fibrosis remodeling prevention by decreasing left
ventricular wall thickness and intercellular and
peripheral collagen volume, and increasing synthesis of
nitric oxide and cyclic adenosine monophosphate.
[18]
Berberine 100 mg/kg
(orally)
Cardiac dysfunction and
remodeling in diabetic
cardiomyopathy (DCM)
In vivo Improvement of cardiac dysfunction and remodeling by
increasing AMPK and Akt, and GSK3β reduction and
Wnt signaling inhibition.
[179]
Berberine 10 μM Cardiac dysfunction and
remodeling in diabetic
cardiomyopathy (DCM)
In vitro Improvement of cardiac dysfunction and remodeling by
increasing AMPK and Akt, and GSK3β reduction, and
Wnt signaling inhibition.
[25]
Berberine 100 and
150 mg/kg/-
day (orally)
Cardiac fibrosis in diabetic rats In vivo Cardiac fibrosis improvement and prevention by
decreasing the expression of transforming growth
factor-β1 (TGF-β1) and connective tissue growth factor
(CTGF) and reducing the synthesis of types I and III
collagen fibers and decreasing undesirable deposition of
these collagen fibers.
[180]
Berberine 10, 30, and
60 mg/kg/-
day (orally)
Cardiac fibrosis In vivo Improvement of cardiac fibrosis by reducing the invasion
of macrophages into the heart tissue and inhibiting
TGF-β1/Smads signaling pathways
[181]
Berberine 1.5 mg/kg
(injection)
Cardiac remodeling and
dysfunction after myocardial
infarction
In vivo Protection of heart function and prevention heart
remodeling by reducing the invasion of macrophages
into the heart tissue, and Il-6 reduction.
[182]
Berberine 30 and
60 mg/kg/-
day (orally)
Acute ischemic myocardial injury In vivo Berberine protects myocardial ischemia and cardiac
undesirable remodeling by reduction the production of
interleukin-6 in macrophages, tumor necrosis factor α
(TNFα), and creatine kinase-MB in cardiac cells
through the HMGB1-TLR4 axis.
[27]
Berberine 20 and
100 μmol/l
(injection)
Cardiac fibrosis In vivo Berberine stimulates the formation of quaternary regions
of guanine, which increases the expression of the relaxin
gene and prevents cardiac fibrosis.
[1]
Berberine 20 μmol/l Cardiac fibrosis In vitro Berberine stimulates the formation of quaternary regions
of guanine, which increases the expression of the relaxin
gene and prevents cardiac fibrosis.
[1]
Berberine 20 mg/kg
(orally)
Cardiac remodeling of heart
failure after myocardial
infarction
In vivo Berberine has been implicated in suppressing cardiac
fibrosis and improving cardiac function by ERS
reduction, CHOP and caspase-12 apoptosis signaling
pathway inhibition, and increased Bcl-2/Bax
expression, and decreased caspase-3 expression.
[36]
Berberine 10 and
50 mg/kg/-
day (orally)
Adverse left ventricular
remodeling and cardiac
dysfunction after myocardial
infarction
In vivo Berberine is able to prevent cardiovascular system fibrosis
by blocking the p38 mitogen-activated protein kinase
signaling pathway and activating the phospho-Akt
pathway.
[37]
Berberine 20 μM Cardiac fibrosis In vitro Berberine in cardiac fibroblasts improves cardiac fibrosis
by activating the AMPK pathway and blocking the
mTOR/p70S6K signaling pathway.
[38]
Berberine 200 mg/kg/day
(orally)
Autoimmune myocarditis In vivo Anti-inflammatory effect of berberine improves cardiac
fibrosis by reducing the phosphorylation of STAT1,
STAT3, and STAT4 and inhibiting Th17 and Th1
differentiation.
[43]
Berberine 200 mg/kg/d
(orally)
Myocardial ischemia/reperfusion
injury
In vivo Berberine, with its antioxidant properties mediated by the
SIRT1 and Foxo1 pathways, could have therapeutic
potential in ameliorating IRI injury and its associated
cardiac fibrosis.
[46]
Curcumin 20 μmol/L Cardiac fibrosis In vitro Curcumin can be involved in the treatment and
improvement of cardiac fibrosis with its anti-fibrotic
potential through p38 MAPK/ERK signaling pathway.
[59]
Curcumin 300 mg/kg/d
(orally)
Cardiac fibrosis in diabetic
cardiomyopathy (DCM)
Curcumin decreases collagen synthesis by inhibiting the
AMPK/p38 MAPK pathway induction of TGF-β1 or
diabetic conditions and prevents cardiac fibrosis.
[63]
Tetrahydrocurcumin 1% Cardiac hypertrophy In vivo [67]
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Table 1 (continued)
Nutraceuticals Doses Problem Model Findings Ref
Curcumin treatment can reduce cardiac oxidative stress
and improve cardiac disorders such as hypertrophy and
cardiac fibrosis in CKD.
Tetrahydrocurcumin 120 mg/kg/d
(orally)
Cardiac fibrosis in diabetic
cardiomyopathy (DCM)
In vivo THC can improve cardiac fibrosis by inhibiting
TGFβ1/Smad3 profibrotic signaling pathway via
SIRT1-induced attenuation of ROS generation.
[75]
Curcumin 200 mg/kg/day
(orally)
Cardiac hypertrophy and fibrosis In vivo Curcumin can prevent cardiac fibrosis by inhibiting
autophagy and activating the mTOR signaling pathway.
[85]
Curcumin 150 or
300 mg/kg/-
day (orally)
Cardiac fibrosis In vivo Curcumin can suppress the differentiation of
myofibroblasts and decrease the expression of TGF-β1,
MMP-9, and TIMP-1 and prevent cardiac fibrosis.
[93]
Curcumin 100 mg/kg/day
(orally)
Curcumin can improve cardiac fibrosis by affecting the
PPAR-γ and TGF-β/Smad2/3 pathway.
[95]
Curcumin 5, 10,
20 μmol/L
Cardiac fibrosis in spontaneously
hypertensive
In vitro Curcumin can improve cardiac fibrosis by affecting the
PPAR-γ and TGF-β/Smad2/3 pathway, and suppress-
ing Ang II-induced production of CTGF, PAI-1, and
ECM in CFs.
[95]
Curcumin 100 mg/kg/day
(orally)
Myocardial infarction-induced
cardiac fibrosis
In vivo Curcumin can prevent cardiac fibrosis by activating
SIRT1.
[117]
Curcumin 5, 10, and
15 μM
Myocardial infarction-induced
cardiac fibrosis
In vitro Curcumin can prevent cardiac fibrosis by activating
SIRT1.
[117]
Hibiscus sabdariffa
(Roselle)
100 mg/kg
(orally)
Cardiac functional and structural
abnormalities in type 1 diabetes
In vivo Roselle stimulates antioxidant activity and can improve
cardiac fibrosis by lowering plasma glucose levels,
cardiac oxidative stress markers, and lipid profile.
[120]
Hibiscus sabdariffa
(Roselle)
100 mg/kg
(orally)
Obesity-induced myocardial
infarction
In vivo Roselle can improve cardiac function by reducing
oxidative stress and prevent cardiac hypertrophy and
fibrosis.
[124]
Flaxseed - Arrhythmia and left ventricular
dilatation after myocardial
infarction
In vivo Flaxseed with beneficial substances such as ALA and
SDG by inhibiting inflammatory reactions can improve
cardiac fibrosis.
[126]
Olive oil
(oleuropein)
20 μg/g Oxidative myocardial injury In vitro Oleuropein can reduce oxidative stress and inflammatory
reactions in the heart tissue.
[143]
Olive oil 4.3 and
6.5 mg/kg
(orally)
Hepatic and cardiac injury In vivo Olive oil can reduce the levels of inflammatory factors
such as tumor necrosis factor-alpha and interleukin-6,
inhibit collagen deposition, and prevent d cardiac fi-
brosis.
[145]
Garlic (Allicin) 1 mL/100-g
body weight
(orally)
Cardiac hypertrophy and fibrosis In vivo Allicin can improve cardiac function and inhibit cardiac
fibrosis by suppressing the ROS-dependent pathway of
ERK1/2, JNK1/2, and PI3K/Akt/GSK3β, NF-κB and
Smad signaling.
[150]
Garlic (Allicin) 10 μM Cardiac hypertrophy and fibrosis In vitro Allicin can improve cardiac function and inhibit cardiac
fibrosis by suppressing the ROS-dependent pathway of
ERK1/2, JNK1/2, and PI3K/Akt/GSK3β, NF-κB and
Smad signaling.
[150]
Garlic (Allicin) - Cardiac fibrosis In vivo Allicin can inhibit cardiac fibrosis by targeting the
TGFβ1/Smads pathway.
[169]
Garlic (Alliin) 100 mg/kg Myocardial infarction In vivo Alliin, by affecting PPAR-γ, stimulates autophagy in
cardiac cells and prevents necrosis and fibrosis induced
by hypoxic conditions.
[175]
Garlic (Alliin) 25, 100, and
200 μg/mL
Myocardial infarction In vitro Alliin, by affecting PPAR-γ, stimulates autophagy in
cardiac cells and prevents necrosis and fibrosis induced
by hypoxic conditions.
[175]
Garlic (Allicin) 250 mg/kg/day
(orally)
Cardiac hypertrophy In vivo Garlic and its metabolites play an important role in the
prevention of cardiac hypertrophy and myocardial
fibrosis with their mechanism of action to increase
Na+/K+ pump.
[178]
Garlic (Allicin) 0.25 mg/mL Cardiac hypertrophy In vitro Garlic and its metabolites play an important role in the
prevention of cardiac hypertrophy and myocardial
fibrosis with their mechanism of action to increase
Na+/K+ pump.
[178]
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Berberine and macrophage-derived agents
Macrophages alter extracellular matrix by phagocytosis and
production of cytokines, including tumor necrosis factor α,
interleukin-6, interleukin-1β, and other factors such as
TGF-β and a monocyte chemotac t i c pro te in -1 .
Myofibroblasts which are adjacent to macrophages produce
collagen [30]. Studies have shown that berberine can reduce
the production of interleukin-6 in macrophages, as well as
tumor necrosis factor α (TNF-α), and creatine kinase-MB in
cardiac cells by influencing the HMGB1-TLR4 axis [30–32].
Berberine reduces the penetration of macrophages and pre-
vents the differentiation of fibroblasts into myofibroblasts.
As a result, it might have a protective role preventing cardiac
fibrosis.
Berberine and relaxin gene expression
Relaxin is an insulin-like hormone that has anti-fibrotic prop-
erties in non-reproductive tumors and tissues, including the
skin and lungs. Therefore, relaxin might be used to treat dis-
eases such as tissue fibrosis (in the heart and the liver) and
solid tumors [33]. The gene deficiency responsible for the
expression of relaxin causes cardiac fibrosis due to aging
[34]. As a result of this, because of eliminating the anti-
fibrotic action hormone, cardiac fibrosis progresses and com-
promises the normal diastolic function of the heart [1, 35–37].
Normal levels of relaxin can improve heart function in patients
with heart failure. Studies have shown that elevated levels of
this hormone can prevent the progression of myocardial fibro-
sis and cardiac dysfunction, on a minor scale [38–40]. Gu et al.
[1] found the presence of guanine-rich sequences in the relaxin
gene promoter that forms a quadruple-rich region of guanine.
Berberine uses this quadrilateral region as its ligand. The
guanine-rich sequences and the quaternary region of the gua-
nine bind to the STAT3 transcription factor activator. Thus,
the STAT3 transcription factor, which inhibits relaxin expres-
sion, cannot be activated. In this study, it has been shown that
berberine stimulates the formation of these guanine quadrants.
The quaternary regions of guanine inhibit it by binding to the
STAT transducer and increase the expression of relaxin. In
mice and cultured cardiac fibroblasts that are treated with an-
giotensin II, berberine can decrease collagen fibers synthesis,
activation of fibroblasts, and progression of cardiac fibrosis by
increasing the expression of relaxin. The anti-fibrotic effect of
berberine is similar to that of relaxin [1]. Therefore, berberine
might be a novel therapeutic approach for prevention of car-
diac fibrosis by increasing the expression of relaxin.
Berberine and endoplasmic reticulum stress
After myocardial infarction, myocardial fibrosis and apoptosis
develop in the infarcted area. Studies show that berberine can
improve myocardial fibrosis and reduce apoptosis. Berberine
reduces endoplasmic reticulum stress (ERS) caused by myo-
cardial infarction. The mechanism of action of berberine to
inhibit adverse cardiac remodeling and cardiac fibrosis can
be attributed to the inhibition of myocardial cell apoptosis
after myocardial infarction. Berberine reduces ERS and in-
hibits CHOP and caspase-12 apoptosis signaling pathways.
On the other hand, it increases Bcl-2/Bax expression and de-
creases caspase-3 expression. Thus, berberine has been impli-
cated in decreasing cardiac fibrosis and improving cardiac
function [41]. Administration of berberine to rats with myo-
cardial infarction reduces intercellular fibrosis in their hearts
and adverse cardiac remodeling. This might be another bene-
ficial mechanism of action of berberine on cardiovascular sys-
tem. Berberine might have a cardioprotective role due to in-
creased expression of LC3-II/I and Beclin-1 as well. Berberine
is also able to prevent cardiovascular system fibrosis by
blocking the p38 mitogen-activated protein kinase signaling
pathway and activating the phospho-Akt pathway. This com-
bination of effects prevents left ventricular regeneration and
subsequent cardiac dysfunction by stimulating autophagy fol-
lowing myocardial infarction [42].
Berberine and mTOR/p70S6K signal transduction
pathway
Studies show that in type II diabetes and obesity, berberine
improves glucose uptake, insulin resistance, and kidney func-
tion. Berberine has beneficial effects on cardiovascular dis-
ease by activating the AMPK pathway [24, 43–46]. In cardiac
fibroblast cells, berberine reduces the proliferation of fibro-
blasts and reduces the expression of alpha-actin filaments of
smooth muscle and collagen. Berberine also inhibits TGFβ1
protein secretion. In cardiac cells treated with berberine,
AMPK phosphorylation increased, whereas mTOR and
p70S6K phosphorylation decreased [43]. mTOR/p70S6K in-
creases myosin heavy chain levels in cardiac tissue and causes
cardiac hypertrophy [47]. Berberine might, therefore, be a
new therapeutic approach for dealing with cardiac fibrosis.
Berberine and inflammation
Autoimmune myocarditis occurs as a result of immune dys-
function and inflammatory reaction [48, 49]. Th17 and Th1
are the crucial cells involved in inflammatory responses that
participate in autoimmune myocarditis pathogenesis by se-
creting inflammatory cytokines IL-17 and IFN-γ, respectively
[48, 50]. Recent studies have shown that berberine can be
effective in reducing adverse reactions of the immune system.
In a study by Liu et al. [48] in myosin-induced injury in rats,
berberine and AG490 (JAK inhibitor) dramatically improved
cardiac dysfunction. Both substances also prevented increased
levels of anti-cardiac myosin antibodies [48]. Berberine and
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AG490 reduced the inflammatory responses induced by Th17
and Th1 activities in cardiac tissue in autoimmune myocardi-
tis. The levels of phosphorylated proteins in the JAK-STAT
pathway, which is the most important pathway in the regula-
tion of Th17 and Th1, were increased in myocarditis induced
by the autoimmune reaction. STAT1, STAT3, and STAT4 are
the most important proteins in this pathway that increase their
phosphorylation during development of autoimmune myocar-
ditis. In this study, berberine, with its anti-inflammatory activ-
ity, reduced the level of phosphorylation of these proteins in
rat autoimmune myocarditis and prevented Th17 and Th1 cell
differentiation [48].
Berberine and oxidative stress
Ischemia-reperfusion injury (IRI) is the leading cause of heart
failure and mortality after myocardial infarction. Oxidative
stress induced by reactive oxygen species (ROS) in the acute
reperfusion plays a central role in the etiopathogenesis of IRI.
Oxygen-reactive species cause severe cardiac damage by in-
ducing chemotactic leukocytes and inflammation. Therefore,
protecting cardiomyocytes from ROS injury might be a rea-
sonable way to improve IRI [51]. CPU86017 berberine-
derived compound has antioxidant effects in chronic heart
failure. In fact, there are indications that berberine reduces
IRI in oxidative stress [51, 52]. In vitro and in vivo findings
indicate that berberine achieves its antioxidant activity by re-
ducingmalondialdehyde (MDA) levels, by decreasing cardiac
superoxide production, and by increasing cardiac superoxide
dismutase (SOD) levels. The results of in vitro and in vivo
studies indicate that berberine can increase Sirtuin 1 (SIRT1)
expression. SIRT1 deacetylase activity in IRI plays an impor-
tant role in cardiovascular protection. SIRT1 interferes with
the regulation of Foxo1 acetylation in cardiac apoptotic path-
ways. Studies have shown that SIRT1 upregulates antioxi-
dants and reduces proapoptotic molecules by influencing
Foxo1. Therefore, it might protect the heart muscle in IRI by
suppressing oxidative stress [51]. It could be concluded that
berberine, with its antioxidant properties mediated by the
SIRT1 and Foxo1 pathways, might have therapeutic potential
in decreasing IRI and cardiac fibrosis as its consequence.
Curcumin
Curcumin is a natural polyphenolic compound that can be
extracted from Curcuma longa L. [53, 54]. Curcumin has
several beneficial properties, including anti-apoptotic, antiox-
idant, anti-cell proliferative, antidiabetic, and anti-
inflammatory [53–55]. The prophylactic effects of curcumin
have been shown in diseases such as liver, kidney, and lung
fibrosis [56–60]. Studies have shown that curcumin has a
beneficial role especially in myocardial infarction and
myocardial injury, but also in hypertension. Its protective role
in myocardial diseases is mainly due to its anti-inflammatory
properties [61–63]. However, the anti-fibrotic effect of
curcumin on cardiac fibrosis is still controversial.
Curcumin and p38 MAPK/ERK signaling pathway
Profibrotic cytokine called transforming growth factor-β1
plays a key role in initiating fibrotic processes [64, 65].
TGF-β1 is involved in differentiation of fibroblasts into
myofibroblasts. Myofibroblasts are cells with high potential
for proliferation, translocation, collagen production, and con-
traction [65–67]. To investigate the mechanism of possible
curcumin’s anti-fibrotic function in cardiac fibrosis, Fang
et al. performed a study on human cardiac fibroblasts
in vitro incubating them with TGF-β1 and curcumin [65].
When measuring the expression of collagen types I and III,
alpha-smooth muscle actin was found to decrease the expres-
sion of these substances in cardiac fibroblasts in the presence
of curcumin. Curcumin inhibited cellular differentiation and
collagen deposition by inhibiting the effects of TGF-β1.
Curcumin also inhibited the proliferation of cardiac fibroblasts
that were exposed to TGF-β1. Curcumin also promoted G2/M
phase cell cycle arrest. Curcumin decreased the expression of
cell cycle proteins by inhibiting Smad 2/3, p38 mitogen-
activated protein kinase, and extracellular regulated protein
kinases (ERK) phosphorylation in cardiac fibroblasts as well
[65]. Therefore, curcumin could be useful in treatment and
improvement of cardiac fibrosis because of its anti-fibrotic
potential through p38 MAPK/ERK signaling pathway.
Curcumin and AMPK/p38 MAPK signaling pathway
AMPK, a serine/threonine kinase, is a cell energy sensor [68,
69]. This kinase protein participates in most cellular processes
including inflammation, cell death or apoptosis, cell prolifer-
ation, and stimulation of cytokine production. AMPK is in-
volved in the fibrosis of different tissues including cardiac
fibrosis [69–71]. It interacts with growth factor signaling path-
ways to affect the process of cardiac fibrosis due to aging,
metabolic syndrome, hypertrophy, and ischemia [24, 69].
Studies show that curcumin can prevent cardiac fibrosis in
diabetes by reducing collagen synthesis [69]. In the study of
Guo et al. [69] on cardiac fibroblasts of diabetic mice, both
in vitro and in vitro, this has been clearly shown. In their study,
after in vitro treatment of diabetic rats’ cells with curcumin and
oral administration of curcumin to diabetic rats, curcumin re-
duced TGF-β1 production, suppressed membrane-bound
TGF-β type II receptors (TβR II), and reduced types I and
III collagen deposition. Curcumin also decreased the level of
phosphorylation of Smad2/3 and increased the level of Smad7
expression. Curcumin reduced the phosphorylation of AMPK
and p38 MAPK, which is enhanced by TGF-β1 in fibroblasts
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in diabetes [69]. Hence, curcumin supressed diabetes-
associated collagen synthesis in myocardium by inhibiting
the AMPK/p38 MAPK pathway as well as by inhibiting
TGF-β1 production and canonical Smad signaling induction
of TGF-β1, thus preventing cardiac fibrosis.
Tetrahydrocurcumin and oxidative stress
Complications of chronic kidney disease (CKD) are caused by
the complex reactions of inflammatory factors, oxidative
stress, and fibrosis. Oxidative stress mediates the inflammato-
ry process due to harmful effects of ROS. Oxidative stress and
inflammation participate also in atherosclerosclerotic cardio-
vascular disease. Clinical trials have shown that the leading
causes of death in CKD are cardiovascular disease, hyperten-
sion, cardiac hypertrophy, and cardiac fibrosis [72–75]. In
CKD, the levels of antioxidant proteins such as copper-zinc
superoxide dismutase (CuZn SOD) and glutathione peroxi-
dase are reduced, but the levels of apoptotic markers, espe-
cially caspase-3, and fibrosis markers, especially alpha-
smooth muscle actin, are increased [72, 76–79]. It can be
concluded that the decrease in antioxidant proteins and the
increase in apoptosis and fibrosis markers also participate in
the development of hypertrophy and cardiac fibrosis.
Tetrahydrocurcumin is a derivative of curcumin that has anti-
oxidant properties [72]. A study by Lao et al. [72] on mice
with CKD showed that tetrahydrocurcumin increases the
levels of antioxidant proteins-copper-zinc superoxide dismut-
ase and glutathione peroxidase. This study indicated that
tetrahydrocurcumin can inhibit the production of ROS, the
process of fibrosis, and apoptosis [72]. Therefore, curcumin
treatment could reduce cardiac oxidative stress by the increase
in antioxidant proteins and the decrease in apoptosis and fi-
brosis markers, and then improve cardiac hypertrophy and
fibrosis in CKD.
Tetrahydrocurcumin and TGFβ1/Smad3 profibrotic
signaling pathway via SIRT1-induced attenuation of
ROS generation
Diabetic cardiomyopathy is characterized by functional im-
pairment of the left ventricle, hypertrophy, apoptosis, and car-
diac fibrosis [80–82]. Several factors including energy imbal-
ance, inflammation, mitochondrial dysfunction, oxidative
stress, and fibrosis are predisposing factors for diabetic car-
diomyopathy [83–85]. SIRT1 participates in many cellular
processes including proliferation, longevity, DNA repair, ag-
ing, inflammation, apoptosis, and cell metabolism [80, 86,
87]. It has been shown recently that SIRT1 is a mediator in
the protective process by which some medicinal plants could
ameliorate the adverse effects of ischemia, reducing oxidative
stress and apoptosis [51, 88]. A study by Li et al. [80] showed
that oral administration of tetrahydrocurcumin (THC) to
diabetic mice reduced the production of ROS and significantly
improved cardiac function, cardiac hypertrophy, and myocar-
dial fibrosis. This study also found that THC enhances the
SIRT1 signaling pathway both in vitro and in vivo. This com-
pound enhances the antioxidant stress capacity by inducing
function of antioxidant enzymes such as superoxide dismutase
and glutathione peroxidase and by reducingMDA production.
THC reduces the expression of cardiac fibrosis markers in-
cluding alpha-smooth muscle actin, collagen I, and collagen
III by blocking ROS-induced TGFβ1/Smad3 signaling path-
way, thus suggesting its possible therapeutic role in cardiac
fibrosis [80]. THC improves cardiac fibrosis by inhibiting
TGFβ1/Smad3 profibrotic signaling pathway via SIRT1-
induced suppression of ROS generation.
Curcumin and mTOR/autophagy axis
Hashemzaei et al. [89] suggested that curcumin stimulates
autophagy by Beclin-1-dependent or Beclin-1-independent
pathways [89]. Curcumin prevents the effects of oxidative
stress-induced damage to human vascular endothelial cells
[90, 91]. Curcumin can achieve its protective role on heart
cells by activating the AMPK signaling pathway and blocking
mTOR signaling, which stimulate autophagy [92]. However,
some studies showed that curcumin protects cardiac cells
against hypoxic damage by inhibiting autophagy [90]. Liu
et al. [90] explained the beneficial effect of curcumin in the
prevention of cardiac fibrosis and cardiac hypertrophy in the
rat model by the mTOR/autophagy signaling pathway. The
results of their study on mice showed that curcumin could
prevent cardiac fibrosis by inhibiting autophagy and activat-
ing the mTOR signaling pathway [90].
Curcumin and transforming growth factor β1 and
matrix metalloproteinase 9/tissue inhibitor of metal-
loproteinase 1
TGF-β1, MMPs, and tissue inhibitor of metalloproteinases
(TIMPs) are the major contributing factors to extracellular
matrix degradation [93–96]. TGF-β signaling is one of the
most important factors involved in the differentiation of
myofibroblasts. It also causes cardiac fibrosis by increasing
the production of extracellular matrix proteins and by
inhibiting MMP activity [97]. Ma et al. [98] have found in a
study on mice with cardiac fibrosis that curcumin could re-
duce the expression of type I and type III cardiac collagen and
collagen deposition between myocardial cells and vessel
walls. It was also found that curcumin directly suppresses
angiotensin II-induced fibroblast proliferation and types I
and III collagen expression in cardiac fibroblasts. The results
of this study indicated that curcumin could suppress the dif-
ferentiation of myofibroblasts and decrease the expression of
TGF-β1, MMP-9, and TIMP-1. Therefore, it could be
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concluded that curcumin plays a role in the inhibition of car-
diac fibrosis [98].
Curcumin and PPAR-γ and TGF-β1/Smad2/3 signaling
Angiotensin II (Ang II) expression is increased in arterial hy-
pertension and in myocardial infarction [99–101]. Elevated
Ang II levels induce proliferation and migration of cardiac
fibroblasts and stimulate apoptosis in myocardial cells.
Increased proliferation and differentiation of fibroblasts and
uncontrolled apoptosis of cells cause deposition of extracellu-
lar matrix proteins, including types I and III collagen (Col I
and Col III) and fibrinectin (FN). Together, these events sup-
port the fibrosis process of the heart [100–103]. Some studies
show that Ang II increases the level of TGF-β expression in
cardiac fibroblasts, and TGF-β signaling is involved in cardi-
ac fibrosis by increasing the production of extracellular matrix
proteins [100].
Another factor that participates in the process of fibrosis in
various tissues such as the heart, kidney, and lung is plasmin-
ogen activator inhibitor (PAI)-1, a member of the of serine
protease inhibitors family. PAI-1 increases the production of
extracellular matrix proteins. It also decreases extracellular
matrix degradation and inhibits matrix metalloproteinase ac-
tivity [100, 102, 104]. Studies have shown that PAI-1 expres-
sion is increased in cardiac fibroblasts and myocardial cells in
the presence of Ang II [105, 106]. CTGF, with its profibrotic
potential, participates in accelerating the progression of car-
diovascular fibrosis by stimulating the proliferation of cardiac
fibroblasts and vascular smooth muscle cells [107, 108].
Studies show that Ang II increases CTGF expression [109].
Therefore, CTGF has been implicated as a functional mediator
of Ang II in the development of cardiac fibrosis [100]. Smad2/
3 is the first target of the TGF-β signaling pathway that is
involved in the expression of CTGF and PAI and the produc-
tion of extracellular matrix proteins in various tissues. Smad2/
3 is also a major target of curcumin, which by targeting
Smad2/3 can affect TGF-β signaling and prevent cell prolif-
eration [110–113].
Proliferative peroxisome proliferator-activated receptor (γ)
(PPAR-γ) interferes with various physiological processes in-
cluding regulation of lipids and glucose metabolism, immune
responses, inflammation, and tissue fibrosis. Activated
PPAR-γ can control the expression of its target genes by
binding to PPAR-specific response elements (PPREs) [100,
105, 114, 115]. Regulating PPAR-γ activity can prevent car-
diac fibrosis caused by different diseases such as hyperten-
sion, diabetes, and myocardial infarction [108, 116, 117].
Overexpression of extracellular matrix substances and prolif-
eration of cardiac fibroblasts are mediated by angiotensin II,
which is inhibited by PPAR-γ ligands [100, 105]. Meng et al.
[100] in their study on hypertensive rats have showed that
curcumin inhibits the expression of CTGF, PAI, and
production of extracellular matrix substances that are affected
by Ang II. Therefore, these authors have concluded that
curcumin improves cardiac fibrosis and reduces its adverse
effects by affecting the PPAR-γ and TGF-β/Smad2/3 path-
way [100].
Curcumin and SIRT1 activation
SIRT1 is a member of the mammalian syringe protein family
(SIRT1–SIRT7), which is involved in various biological path-
ways such as DNA damage repair, gene silencing, survival
and metabolism, and cell aging [118]. Studies have shown
that SIRT1 is involved in the fibrosis process of different
tissues including the heart, kidney, and liver [119, 120].
Recent studies suggest that there might be a therapeutic po-
tential of curcumin by activating SIRT1 in ischemia-induced
adverse effects of mitochondrial oxidative damage [121, 122].
Xiao et al. [122], after evaluating SIRT1 expression levels,
extracellular matrix degradation affected by matrix metallo-
proteinases, collagen interstitial deposition, proliferation, and
migration of cardiac fibroblasts, have concluded that
curcumin could prevent cardiac fibrosis by activating SIRT1
in vivo and in vitro [122].
Hibiscus sabdariffa (Roselle)
“Flowers of Jamaica” is a name given to Hibiscus sabdariffa
L. (Roselle), a plant belonging to the Malvaceae family.
Mexico in Central America, Africa, and Southeast Asia are
the areas where this plant grows. Roselle is used in the food
industry as a flavoring agent for sauces, herbal drinks, and dye
in foods. It is popular in some countries as a herbal medicine
as well. Roselle might be beneficial for the cardiovascular
system regulating blood pressure [123], has antidiabetic activ-
ity, and, according to some authors, might improve liver dis-
orders [123]. Studies have shown that the different red sub-
stances in Roselle such as caffeic acid, epigallocatechin-gal-
late, protocatechuic acid, and catechins (polyphenolic com-
pounds) have antioxidant properties and inhibit cyclooxygen-
ase activity [124, 125].
Hibiscus sabdariffa and oxidative stress
Today, with the increasing number of patients with diabetes,
this disease is one of the leading causes of death in the world
[126, 127]. The major complication of diabetes that results
with death is cardiovascular disease (CVD) [128]. Cardiac
fibrosis is one of the mechanisms involved in myocardial dys-
function in CVD [129]. Oxidative stress is one of the most
important causes of functional myocardial disease in patients
with diabetes. It occurs due to hyperlipidemia, hyperglycemia,
and inflammatory reaction. These patients are exposed to
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oxidative stress due to increased production of ROS, reduced
levels of degradation of ROS, and limitation of the body’s
antioxidant activity [126]. Therefore, taking in consideration
the role of oxidative stress in progression of CVD, especially
cardiac fibrosis, it might be concluded that Roselle with its
antioxidant properties could improve hypertrophy and cardiac
fibrosis. Such a therapeutic effect of Roselle has been shown
on diabetic mice in a study by Mohammed et al. [126]. They
have found that Roselle administration could target the pro-
duction of reactive oxygen species in the heart tissue and
improve the cardiac dysfunction and remodeling caused by
diabetes. The same study showed that Roselle lowers plasma
glucose levels and cardiac oxidative stress markers, improves
lipid profile, and stimulates the activity of antioxidant agents
[126].
This role of Roselle in protecting the cardiovascular system
by reducing oxidative stress was also evident in another study
by Si et al. [130]. In this study, performed on a model of obese
rats with cardiac ischemia, Roselle could prevent fibrosis by
improving cardiac function [130]. It seems that this plant can
improve cardiac function and regeneration by regulating the
balance between production and destruction of ROS and by
reducing oxidative stress, thereby preventing hypertrophy and
cardiac fibrosis.
Hibiscus sabdariffa and inflammation
Most deaths because of CVD occur due to extensive and un-
controlled remodeling of the damaged parts of the heart tissue.
Polyphenolic substances in Roselle lower the blood pressure
and have antioxidant properties [131]. Studies have shown
that in mice after myocardial infarction, the plasma levels
and expression of inflammatory cytokines such as interleukins
10 and 6 are increased. Plasma levels of troponin T were also
reduced. In this mice model, due to increased serum inflam-
matory factors, cardiac fibrosis is caused by increased expres-
sion of types I and III collagen. On the other hand, increased
expression of atrial natriuretic peptide (ANP) and brain natri-
uretic peptide (BNP) gene expressions causes cardiac hyper-
trophy and cardiac fibrosis [131]. Therefore, Roselle with its
anti-inflammatory and antioxidant properties seems to have a
potential to prevent fibrosis.
Flaxseed
Flaxseed is one of the plants with high levels of α-linolenic
acid (ALA), one of the essential varieties of omega-3 polyun-
saturated fatty acids (n-3 PUFAs). The sources of ALA are
vegetable oils like flaxseed, canola, and olive oil, while EPA
and DHA are found in fish and marine oils [132]. This plant is
a rich source of lignan phytoestrogen secoisolariciresinol
diglucoside (SDG) and soluble fibers [133, 134]. Studies have
shown that flaxseed has beneficial effects on CVD. The effect
of this plant on blood pressure reduction in patients with pe-
ripheral vascular disease has been reported [135]. It seems that
flaxseed can reduce the plasma levels of atherogenic lipopro-
tein (a).The results of some studies also indicate that flaxseed
can inhibit the formation of atherosclerotic plaques in the mice
model [133, 136, 137]. This plant plays a role in the improve-
ment of ventricular arrhythmia induced by ischemia-
reperfusion [133, 138]. The α-linolenic acid present in flax-
seed seeds inhibits cardiac cell apoptosis in ischemia-
reperfusion by affecting the electrical conductivity of the heart
[139]. Therefore, flaxseed can be used to improve heart func-
tion and arrhythmia, and prevent the progression of cardiac
fibrosis, especially after myocardial infarction.
Flaxseed and inflammatory cytokine TNF-α
Ventricular dilation can occur after myocardial infarction.
This dilation is caused by the left ventricular regeneration
process. Because of this, contractile function of myocardium
will be impaired. Depending upon the extent of left ventricular
dilation, the heart is exposed to risks such as arrhythmia and
heart failure. One of the major contributing factors to abnor-
mal ventricular dilation and remodeling is the inflammatory
process that is triggered by neutrophils, lymphocytes, and
monocytes or macrophages [133, 140–142]. Macrophages
with different growth factors and proinflammatory cytokines
stimulate in the myocardium inflammatory process and sub-
sequently cardiac fibrosis. Monocyte chemoattractant protein-
1(MCP-1), an inflammatory chemokine, increases collagen
expression in cardiac fibroblasts by producing fibrotic cyto-
kines [143, 144]. Studies have shown that adding flaxseed to
the diet can reduce the expression of inflammatory markers
such as mac-3, IL-6, and VCAM-1 in cardiac patients [144].
The proinflammatory cytokine TNF-α is involved in most
heart diseases and can affect the extracellular matrix and car-
diac function. This proinflammatory factor plays a role in the
cardiac fibrosis pathway by affecting its downstream signaling
pathways such as the one based upon TGF-β [145, 146].
Parikh et al. [133] showed the anti-inflammatory role of flax-
seed due to ALA and lignan phytoestrogen SDG. This study
found that flaxseed consumption inhibited the expression of
proinflammatory factor TNF-α and prevented remodeling and
cardiac fibrosis [133]. Therefore, flaxseed with its substances
such as ALA and SDG can be useful ro improve cardiac fi-
brosis by inhibiting inflammatory reaction.
Olive oil
The Mediterranean diet includes ingredients and nutrients that
protect the cardiovascular system. Olive oil is one of the main
components of theMediterranean diet. Olive oil is rich in oleic
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acid and polyphenol hydroxytyrosol and oleuropein
[147–149].
Olive oil and oxidative stress and inflammation
Studies show that the beneficial effects of olive oil on the
cardiovascular system and its role in improving cardiac fibro-
sis are due to the role of the abovementioned substances in
inhibiting inflammatory reaction and oxidative stress. In vitro
studies showed that oleuropein and its important metabolite,
hydroxytyrosol, can reduce oxidative stress and inflammatory
reaction in the heart tissue. These substances from olive oil
have also blood pressure-lowering properties [150, 151]. An
important role of olive oil in control of cardiac fibrosis in vivo
has been confirmed by Poudyal et al. [152]. In their study,
mice treated with olive oil reduced the levels of inflammatory
factors such as tumor necrosis factor-alpha and interleukin-6
and inhibited collagen deposition [152].
Garlic (Allicin)
Garlic (Allium sativum L.) has a long history of use in medi-
cine. Studies have shown antioxidant and antibacterial prop-
erties of garlic. Garlic can also lower blood lipid levels and
inhibit platelet aggregation [153–156]. Allicin is one of the
most important active substances that are found in garlic.
Allicin is involved in the inhibition of lipid peroxidation
[157, 158]. This substance reduces the production of ROS
and increases glutathione levels in endothelial cells [159].
Studies show that allicin inhibits nitric oxide synthase
(iNOS) activity in cardiac cells, while on the other side, nitric
oxide (NO) inhibits the antioxidant property of allicin [160].
Recent data suggest that allicin improves vascular endothelial
dysfunction in the rat model and prevents cardiac hypertrophy
[161]. Therefore, allicin can prevent cardiac fibrosis following
hypertrophy. However, the mechanisms of action of allicin in
the prevention of hypertrophy and cardiac fibrosis have not
yet been fully understood, and further studies are needed.
Garlic and reactive oxygen species-dependent signal-
ing pathways
Studies show that increased ROS activates ASK1 and ASK1
downstream kinases such as JNK1/2 and p38 and initiates the
hypertrophic process through the involvement of cardiac stim-
uli [162]. The impact of ROS on Akt is controversial. One
study has shown that Akt participates in the pathogenesis of
ROS-induced hypertrophy and stimulates its activity [163].
But no other study could confirm such a relationship [164].
Therefore, further studies are needed to better understand the
relationship between ROS and Akt. Liu et al. [157] confirmed
the role of allicin in improving cardiac function and inhibiting
cardiac fibrosis by suppressing the ROS-dependent pathway
of ERK1/2, JNK1/2, and PI3K/Akt/GSK3β in vivo and
in vitro. Allicin was also found to suppress inflammatory
and fibrotic reactions by inhibiting NF-κB and inhibiting
ROS-dependent Smad cascades [157]. Therefore, allicin
might be considered as a useful substance in the treatment of
cardiac fibrosis and evenmaybe prevention of cardiac fibrosis.
Garlic and peroxisome proliferator-activated receptor
gamma and TGFβ/Smads signaling pathways
Studies show that TGF-β is an important factor in the prolif-
eration and differentiation of fibroblasts. TGF-β stimulates
the process of cardiac fibrosis by interfering with the Smad
signaling pathway. Recently, studies have been performed
with substances which block TGF-β and TGF-β target pro-
teins [165–168]. Li et al. [169] showed that thatallicin, the
active ingredient of garlic, inhibited cardiac fibrosis in mice
after myocardial infarction. In these mice, collagen expression
types I and III are significantly increased. In this animal model
with increased TGFβ1, Smad3 expression in cardiac cells
increases the activity of the TGFβ1/Smads pathway. After
treatment with allicin, collagen production was decreased in
cardiac cells, and this substance inhibited TGFβ1 and Smad3
pathway activity. Smad7 expression was also increased in
cardiac cells [169]. Based upon these data, it could be con-
cluded that allicin inhibits cardiac fibrosis by targeting the
TGFβ1/Smads pathway. Studies show that under hypoxia,
allicin increases the expression of LC3 and Beclin-1 in cardiac
cells. It has also been reported that garlic can increase the
levels of LC3 and Beclin-1 in the myocardium of patients with
myocardial infarction [170–172]. PPAR-γ participates in the
regulation of apoptosis and autophagy and is involved in the
regulation of glucose and lipid metabolism. PPAR-γ prevents
post-ischemic heart regeneration by reducing inflammatory
response, apoptosis, and oxidative stress in heart tissue [173,
174]. The effect of alliin, organosulfur substance from garlic,
on the inhibition of myocardium changes, including cardiac
fibrosis, is confirmed by changes in the levels of LC3, Beclin-
1, and PPAR-γ [175]. In this study, alliin, by affecting
PPAR-γ, stimulated autophagy in cardiac cells and prevented
necrosis induced by hypoxia [175]. The conclusion might be
that allicin inhibits cardiac fibrosis via suppression of TGFβ/
Smads signaling pathways.
Garlic and Na+/K+ pump expression
Protein expression and their signaling pathways are altered by
altering mitochondrial function and increasing production of
ROS [176]. These changes can impair the function of the heart
muscle tissue. Throughout the cell membrane of the Na+/K+,
pump (Na+/K+-TPase) acts as an active ions transporter
through the cell membrane. Due to the special function of this
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pump, it can play an important role in controlling the electrical
conductivity of the heart. Therefore, this ion transducer also
influences the contractile function of the heart. Reduced pres-
ence of Na+/K+-ATPase causes arrhythmia, impaired contrac-
tility, and consequently heart failure [176–178]. Therefore,
any chemical or natural substance that can increase the expres-
sion and activity of this pump could contribute to the inhibi-
tion of hypertrophy and cardiac fibrosis. Khatua et al. [178]
showed a significant decrease in the Na+/K+ pump level in
mice with cardiac hypertrophy. This study showed also that
calcium overload may happen to cardiac cells when the pump
is deficient and its activity decreases, increasing the blood
pressure. Khatua et al. have found that administration of garlic
to these mice increased the expression level and activity of the
Na+/K+ pump, and calcium overload in the heart cells de-
creased and prevented cardiac hypertrophy and fibrosis
[178]. Thus, garlic and its metabolites might play a role in
prevention of cardiac hypertrophy and myocardial fibrosis
due to an effect on Na+/K+ pump.
Conclusions
CVD is the leading cause of death worldwide. Many factors
such as dyslipidemia, arterial hypertension, obesity, stress,
and smoking increase the risk for these diseases. In chronic
kidney disease and diabetes, the major cause of death is CVD.
Cardiac fibrosis is one of the important pathological condi-
tions that occur as a consequence of myocardial infarction and
other ischemic damages of the myocardium. Inflammatory
cascades, oxidative stress, imbalance between production
and destruction of extracellular matrix proteins, and prolifer-
ation and differentiation of cardiac fibroblasts contribute to
cardiac fibrosis. As myocardial fibrosis progresses and re-
mains untreated, myocardial tissue loses its contractile func-
tion. The heart dilates as a result of contractile dysfunction to
maintain blood flow, leading to an increased blood pressure.
Arrhythmias and heart failure are complications of cardiac
fibrosis. Therefore, some food components can play an impor-
tant role as the link between food and health of the myocardi-
um. A diet that includes plants and nutraceuticals derived from
plants can also reduce the cost of healthcare. The clinical
research results analyzed in this article suggest that
nutraceuticals may be involved in the cardiac fibrosis signal-
ing pathways that might help to prevent and treat cardiac
fibrosis.
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